We initially assessed responses to navitoclax (targeting BCL-2/BCL-XL), venetoclax (targeting BCL-2), and S63845 (targeting MCL-1) in a series of prostate cancer PDX-derived primary cultures/3D spheroids, patient-derived organoids, and cell lines (Fig. 1a, Supplementary Table S1). This evidence concerns the gene BCL2L1 and prostate carcinoma.